Morningstar

Tema Oncology ETF CANC

Morningstar Medalist Rating
Medalist Rating as of | See Tema ETFs Investment Hub

Morningstar’s Analysis CANC

Will CANC outperform in the future?

Get our overall rating based on a fundamental assessment of the pillars below.

  • Process Pillar

    The Process Pillar is our assessment of how sensible, clearly defined, and repeatable CANC’s performance objective and investment process is for both security selection and portfolio construction.

  • People Pillar

    The People Pillar is our evaluation of the CANC management team’s experience and ability. We find that high-quality management teams deliver superior performance relative to their benchmarks and/or peers.

  • Parent Pillar

    The Parent Pillar is our rating of CANC’s parent organization’s priorities and whether they’re in line with investors’ interests.

null Morningstar Automated Analysis

Morningstar Automated Analysis

Summary

Tema Oncology ETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.

by Morningstar Automated Analysis
Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings CANC

More CANC Holdings
  • Current Portfolio Date
  • Equity Holdings —
  • Bond Holdings —
  • Other Holdings —
  • % Assets in Top 10 Holdings 40.0
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Revolution Medicines Inc Ordinary Shares

5.48 11M
Healthcare

Merck & Co Inc

4.84 10M
Healthcare

Cogent Biosciences Inc

4.72 10M
Healthcare

Eli Lilly and Co

4.55 9M
Healthcare

Novartis AG Registered Shares

3.68 8M
Healthcare

Bristol-Myers Squibb Co

3.45 7M
Healthcare

BeOne Medicines Ltd ADR

3.34 7M
Healthcare

Iovance Biotherapeutics Inc

3.32 7M
Healthcare

AbbVie Inc

3.30 7M
Healthcare

Genmab AS ADR

3.20 7M
Healthcare

Sponsor Center